Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined with EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer

Cheng-Ting Zi

doi:10.26717/bjstr.2019.18.003133

Abstract

Lung cancer is one of the most common malignancies in the world, non-small cell lung cancer (NSCLC) accounting for 85% of all cases of lung cancers [1]..

Highlights

Lung cancer is one of the most common malignancies in the world, non-small cell lung cancer (NSCLC) accounting for 85% of all cases of lung cancers [1]
Our current studies suggest that the combination of epigallocatechin gallate (EGCG) glycosides and Epidermal growth factor receptor (EGFR) TKIs may provide a potential strategy for NSCLC
We test the stability of EGCG and its derivatives according to the amount of hydrogen peroxide (H2O2) which is a by-product of biological oxidation processes

Summary

Introduction

Lung cancer is one of the most common malignancies in the world, non-small cell lung cancer (NSCLC) accounting for 85% of all cases of lung cancers [1]. Epidermal growth factor receptor (EGFR) is an important target in the targeted therapy of NSCLC [2]. It is lo cated in the cell surface and overexpressed in about 50% of NSCLC patients. The inhibition of EGFR signaling by tyrosine kinase inhibitors or monoclonal antibodies plays a key role in NSCLC treatment [4,5]. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs), such as gefitinib and erlotinib have exhibited remarkable therapeutic effects against NSCLC with exon 19 deletions and L858R point activating mutations in EGFR, but resistance arises rapidly in all patients after varying periods of time [6,7]. Due to the limited treatment options available for individuals with advanced lung cancer, the novel strategies to conquer drug resistance is an emergency to prolong overall survival time of NSCLC patients

Methods

Results

Conclusion